CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $11.84B, above the global median of $1.15B
- PositionReturn on equity is -349.4%, lower than 95% of its Biotechnology peers (median 6%)
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
11.84BUSDvs all stocks (USD)
Revenue (TTM)
708.24MUSDvs all stocks (USD)
Profit Margin
-26.59%vs Biotechnology peers
Beta
0.5960xvs all stocks
52-Week Change
109.70%vs all stocks
Market Capitalization
11.84BUSDvs all stocks (USD)
Enterprise Value
12.14BUSDvs all stocks (USD)
Forward P/E
40.35xvs Biotechnology peers
Price to Sales (TTM)
17.22xvs Biotechnology peers
Price to Book (MRQ)
223.20xvs Biotechnology peers
Enterprise to Revenue
17.14xvs Biotechnology peers
Enterprise to EBITDA
-72.58xvs Biotechnology peers
Gross Margin
92.30%vs Biotechnology peers
Profit Margin
-26.59%vs Biotechnology peers
Operating Margin
-32.83%vs Biotechnology peers
Return on Assets (TTM)
-16.84%vs Biotechnology peers
Return on Equity (TTM)
-349.38%vs Biotechnology peers
Revenue (TTM)
708.24MUSDvs all stocks (USD)
Revenue per Share (TTM)
14.07USDUpdated Jul 18, 2026Quarterly Revenue Growth
57.40%vs Biotechnology peers
Gross Profit (TTM)
655.82MUSDvs all stocks (USD)
EBITDA (TTM)
-167.23MUSDvs all stocks (USD)
Net Income (TTM)
-188.30MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
57.42%vs Biotechnology peers
Operating Cash Flow (TTM)
-70.73MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-3.85MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
638.50MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
47.48MUSDFY2025 · Dec 31, 2025Gross Profit
591.02MUSDFY2025 · Dec 31, 2025Operating Income
-169.24MUSDvs all stocks (USD)
Pre-tax Income
-183.70MUSDFY2025 · Dec 31, 2025Income Tax Expense
-530.00KUSDFY2025 · Dec 31, 2025Net Income
-183.17MUSDFY2025 · Dec 31, 2025EBIT
-177.15MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-160.17MUSDFY2025 · Dec 31, 2025Research & Development
183.28MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
570.60MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
6.56MUSDFY2025 · Dec 31, 2025EPS (Basic)
-3.68USDFY2025 · Dec 31, 2025EPS (Diluted)
-3.68USDFY2025 · Dec 31, 2025Basic Shares Outstanding
49.75MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
49.75MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-183.17MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-185.86MUSDFY2025 · Dec 31, 2025Free Cash Flow
-186.34MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
322.93MUSDFY2025 · Dec 31, 2025Interest Paid
14.63MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-183.17MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
9.06MUSDFY2025 · Dec 31, 2025Stock-based Compensation
93.75MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-909.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-82.46MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-6.46MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-15.67MUSDFY2025 · Dec 31, 2025Capital Expenditures
-480.00KUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-480.00KUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
330.00MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-334.11MUSDFY2025 · Dec 31, 2025Other Financing Charges
-21.89MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
41.91MUSDFY2025 · Dec 31, 2025Shares Outstanding
51.42MSharesUpdated Jul 18, 2026Float Shares
43.56MSharesUpdated Jul 18, 2026Shares Short
2.63MSharesUpdated Jul 18, 2026Short Ratio
2.29daysvs all stocks
Short % of Shares Outstanding
8.02%vs all stocks
% Held by Insiders
15.35%vs all stocks
% Held by Institutions
75.64%vs all stocks
Total Cash (MRQ)
305.11MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
5.93USDUpdated Jul 18, 2026Total Debt (MRQ)
219.90MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
4.03xvs Biotechnology peers
Current Ratio (MRQ)
1.39xvs Biotechnology peers
Book Value per Share (MRQ)
1.06USDUpdated Jul 18, 2026Total Assets
689.80MUSDvs all stocks (USD)
Total Current Assets
588.99MUSDFY2025 · Dec 31, 2025Total Liabilities
601.51MUSDFY2025 · Dec 31, 2025Total Non-current Assets
100.82MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
222.67MUSDFY2025 · Dec 31, 2025Total Current Liabilities
378.84MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
322.93MUSDFY2025 · Dec 31, 2025Accounts Receivable
224.46MUSDFY2025 · Dec 31, 2025Inventory
27.94MUSDFY2025 · Dec 31, 2025Accounts Payable
65.54MUSDFY2025 · Dec 31, 2025Short-term Debt
72.98MUSDFY2025 · Dec 31, 2025Other Current Liabilities
10.01MUSDFY2025 · Dec 31, 2025Long-term Debt
145.13MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
77.54MUSDFY2025 · Dec 31, 2025Common Stock (Book)
5.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.31BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
88.30MUSDvs all stocks (USD)
52-Week Low
96.09USDUpdated Jul 18, 202652-Week High
260.19USDUpdated Jul 18, 202652-Week Change
109.70%vs all stocks
Beta
0.5960xvs all stocks
50-Day MA
236.52USDUpdated Jul 18, 2026200-Day MA
178.40USDUpdated Jul 18, 2026Avg 10-Day Volume
711.51KSharesUpdated Jul 18, 2026Avg 30-Day Volume
1.04MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-3.73USDUpdated Jul 18, 2026Other Income / Expense
-7.91MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -349.4%, lower than 95% of its Biotechnology peers (median 6%)Significant
Return on equity: -3.49Industry median: 0.06Industry P5: -1.72Peers compared: 24.00
Debt-to-equity is 4.03×, higher than 95% of its Biotechnology peers (median 0.19×)Significant
Debt-to-equity: 4.03Industry median: 0.19Industry P95: 1.58Peers compared: 24.00
Price-to-book is 223.2×, higher than 95% of its Biotechnology peers (median 7.62×)Significant
Price-to-book: 223.201Industry median: 7.62Industry P95: 35.03Peers compared: 24.00
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.92Profit Margin: -0.27
Significant cash reserves alongside high leverageNotable
Cash (USD): 305,105,984Total Debt (USD): 219,900,000Debt-to-Equity: 4.03
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.53
Altman Z-Score 9.6: safe zoneNotable
Altman Z-Score: 9.60
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $11.84B, above the global median of $1.15BNotable
Market cap (USD): 11,835,746,180Global Median: 1,146,734,693.424
Revenue is $708.24M, above the global median of $520.53MNotable
Revenue (USD): 708,236,032Global Median: 520,528,949.311
Companies that share the same coordination system — how they create, deliver, or capture value.
Haisco Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Recordati Industria Chimica e Farmaceutica S.p.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Cipla Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
CSPC Pharmaceutical Group Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Biomarin Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Insulet Corporation
Tier 1ProductionApproval-Gated PipelineRule
Penumbra Inc.
Tier 1ProductionApproval-Gated PipelineRule
Swedish Orphan Biovitrum AB
Tier 1ProductionApproval-Gated PipelineRuleRisk
Madrigal Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Molina Healthcare Inc.
1 interpretationRevenue Growing With Receivables Growing
Hd Hyundai Heavy Industries Co., Ltd.
1 interpretationRevenue Growing With Receivables Growing
Clean Harbors Inc.
1 interpretationRevenue Growing With Receivables Growing